Long-Circulating Lipid Nanospheres Loaded with Flurbiprofen Axetil for Targeted Rheumatoid Arthritis Treatment

Area of Science:

• Nanotechnology
• Pharmacology
• Rheumatology

Background:

• Flurbiprofen axetil (FA) exhibits anti-inflammatory and analgesic properties but is limited by poor solubility and short circulation.
• Off-target binding of FA restricts its clinical efficacy in treating conditions like rheumatoid arthritis (RA).

Purpose of the Study:

• To develop and evaluate a novel drug delivery system, cRGD-FA-SLM, for targeted RA treatment.
• To investigate the therapeutic potential of stealth lipid microspheres (SLM) modified with arginine-glycine-aspartic acid (RGD) peptide for enhanced FA delivery.

Main Methods:

• cRGD-FA-SLM was prepared using high-pressure homogenization.
• In vitro studies assessed toxicity and macrophage uptake (RAW264.7 cells).
• In vivo evaluation in a collagen-induced arthritis rat model included pharmacokinetics, biodistribution, and therapeutic efficacy assessments.

Main Results:

• cRGD-FA-SLM demonstrated spherical morphology and efficient FA encapsulation.
• The platform showed no toxicity to normal macrophages and selective uptake by activated macrophages in vitro.
• In vivo studies revealed preferential accumulation in arthritic joints, prolonged FA circulation, reduced prostaglandin E2 expression, and alleviation of joint edema and bone erosion.

Conclusions:

• cRGD-FA-SLM possesses excellent inflammation-targeting capabilities and extended in vivo drug circulation.
• The developed RGD-peptide-modified stealth lipid microspheres show significant promise for targeted anti-inflammatory and analgesic therapy in RA.